Virtuous circles in science and commerce

During the formative years of biotechnology, 'star' bioscientists possessed intellectual capital of extraordinary scientific and pecuniary value. In America and Japan, 35 percent of star bioscientists became involved with firms in commercialising their discoveries (a crucial determinant of success) versus 7 percent in Europe. Did star involvement come at expense of scientific progress? No, the publication rate of these 'involved stars' increased very significantly whilst actively involved with firms. Furthermore, citations per article were unchanged or significantly increased; so quality was maintained. Top academic scientists and firms working together led to faster commercial and scientific progress - a truly virtuous circle. Copyright (c) 2007 the author(s). Journal compilation (c) 2007 RSAI.